Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Sep 17, 2024 7:14pm
252 Views
Post# 36228141

RE:Ruvidar will be the go to drug when we get to trials.

RE:Ruvidar will be the go to drug when we get to trials.
O12009 wrote:
  • An antibody-drug conjugate developed by Daiichi Sankyo and Merck & Co. met the main goal of a Phase 3 lung cancer trial, delaying tumor progression in people whose disease has a specific mutation by longer than chemotherapy, the companies said Tuesday.
  • The companies didn’t release detailed data from the trial, which tested patritumab deruxtecan against a two-drug chemo combination in people whose non-small cell lung cancer has a mutation in a gene called EGFR. The trial enrolled people whose disease had progressed following treatment with EGFR-targeting drugs.
  • One year ago, Daiichi reported positive data from a Phase 2 trial that were sufficient to support an application to the Food and Drug Administration for accelerated approval and attract billions of dollars in Merck partnering cash. However, the FDA rejected Daiichi’s application over inspection findings at a manufacturing plant.
  • Daiichi and Merck’s drug, like the others in its class, use an antibody to home in on a protein expressed on tumor cells and then release a toxic chemical directly to diseased cells. The first ADCs were in blood cancers, but more and more drugmakers are developing them for solid tumors like those of the breast and bladder.

    Their development has been helped along by Daiichi, which discovered the breast cancer ADC Enhertu — one of the most successful drugs in the class. Enhertu, which AstraZeneca helps market, had sales of $1.8 billion through the first six months of the year.

    The Japan-based drugmaker has a total of six ADCs using the deruxtecan chemotherapy. Those include Enhertu, another agent partnered with AstraZeneca, an additional two drugs partnered with Merck and one Daiichi is developing alone.

    The Merck deal saw the New Jersey-based drugmaker pledge up to $22 billion, including $3 billion on the deal’s signing last October. Merck is seeking to boost its pipeline as it faces a potential loss of revenue later in the decade when key patents for its immunotherapy Keytruda begin to expire.

    The type of lung cancer patritumab deruxtecan is being tested in is usually treated first with EGFR-blocking small molecule drugs like AstraZeneca’s Tagrisso. The cancer typically becomes resistant to those agents over time and, once that happens, people have a poor outlook and few effective drug options.

    In the Phase 2 trial Daiichi reported last year, people who received patritumab deruxtecan went a median of six months before their disease progressed again, and three in 10 people who received it had their tumors shrink or disappear.


Our numbers with Ruvidar and a chemotherapy combined will be much better. Get ready for a great ending in 2024 and new trials after financing. IMO




I agree...we have a great opportunity to either assist, fill in the gaps, or eventually replace ADCs for specific indications/less manageable cancers.

The ADC reported is only specific for EGFR mutations in NSCLC, which represents ~32% of NSCLC cases worldwide per WebMD (Oct. 11, 2023).  In other words, a "majority" of NSCLC patients are not candidates for this ADC.  In those patients who qualified, the ADC buys you only a median of 6 months progression-free disease...not spectacular imo.  Furthermore, as with other ADCs, you run the relatively high risk of triggering cancer resistance in this stubborn form of cancer.  Lastly, ADCs are biologics, which generally involve a more complex manufacturing process wherein many potential points of failure exist in terms of QA...the precise reason why the FDA rejected Daiichi's application for AA.

Merck can't afford to be asleep at the wheel for much longer...& a BTD with $10+ million in the bank should help change that.  Speaking of BTD, TLD 1433's structural novelty should also work in our favor, generally speaking.  Structually novel drugs are more than twice as likely to be granted BTD status by the FDA (per the American Chemical Society/CAS article, Sept. 23, 2022).  Our odds for success continue to grow. All imo.


<< Previous
Bullboard Posts
Next >>